Cargando…
Treatable traits in the NOVELTY study
BACKGROUND AND OBJECTIVE: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and dis...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795904/ https://www.ncbi.nlm.nih.gov/pubmed/35861464 http://dx.doi.org/10.1111/resp.14325 |
_version_ | 1784860359532740608 |
---|---|
author | Agustí, Alvar Rapsomaniki, Eleni Beasley, Richard Hughes, Rod Müllerová, Hana Papi, Alberto Pavord, Ian D. van den Berge, Maarten Faner, Rosa |
author_facet | Agustí, Alvar Rapsomaniki, Eleni Beasley, Richard Hughes, Rod Müllerová, Hana Papi, Alberto Pavord, Ian D. van den Berge, Maarten Faner, Rosa |
author_sort | Agustí, Alvar |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real‐world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. METHODS: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real‐world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (n = 5932, 52.8%), ‘COPD’ (n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). RESULTS: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. CONCLUSION: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real‐world setting to date. |
format | Online Article Text |
id | pubmed-9795904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-97959042022-12-28 Treatable traits in the NOVELTY study Agustí, Alvar Rapsomaniki, Eleni Beasley, Richard Hughes, Rod Müllerová, Hana Papi, Alberto Pavord, Ian D. van den Berge, Maarten Faner, Rosa Respirology ORIGINAL ARTICLES BACKGROUND AND OBJECTIVE: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real‐world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of ‘asthma’, ‘COPD’ or ‘asthma + COPD’. METHODS: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real‐world setting, both in primary care clinics and specialized centres, for patients with ‘asthma’ (n = 5932, 52.8%), ‘COPD’ (n = 3898, 34.7%) or both (‘asthma + COPD’; n = 1396, 12.4%). RESULTS: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with ‘asthma’, ‘COPD’ and ‘asthma + COPD’, respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. CONCLUSION: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real‐world setting to date. John Wiley & Sons, Ltd 2022-07-21 2022-11 /pmc/articles/PMC9795904/ /pubmed/35861464 http://dx.doi.org/10.1111/resp.14325 Text en © 2022 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | ORIGINAL ARTICLES Agustí, Alvar Rapsomaniki, Eleni Beasley, Richard Hughes, Rod Müllerová, Hana Papi, Alberto Pavord, Ian D. van den Berge, Maarten Faner, Rosa Treatable traits in the NOVELTY study |
title | Treatable traits in the NOVELTY study |
title_full | Treatable traits in the NOVELTY study |
title_fullStr | Treatable traits in the NOVELTY study |
title_full_unstemmed | Treatable traits in the NOVELTY study |
title_short | Treatable traits in the NOVELTY study |
title_sort | treatable traits in the novelty study |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795904/ https://www.ncbi.nlm.nih.gov/pubmed/35861464 http://dx.doi.org/10.1111/resp.14325 |
work_keys_str_mv | AT agustialvar treatabletraitsinthenoveltystudy AT rapsomanikieleni treatabletraitsinthenoveltystudy AT beasleyrichard treatabletraitsinthenoveltystudy AT hughesrod treatabletraitsinthenoveltystudy AT mullerovahana treatabletraitsinthenoveltystudy AT papialberto treatabletraitsinthenoveltystudy AT pavordiand treatabletraitsinthenoveltystudy AT vandenbergemaarten treatabletraitsinthenoveltystudy AT fanerrosa treatabletraitsinthenoveltystudy AT treatabletraitsinthenoveltystudy |